eye regener thursday et cet full data
intercept phase regener trial obetichol acid oca
nonalcohol steatohepat nash present minut session
anchor posit open ceremoni annual meet
intern liver congress ilc european associ
studi liver easl follow keynot present intercept
host investor event et cet dial
mani question remain answer among key piec
inform would like see thursday look detail
fibrosi improv base initi fibrosi stage prevent fibrosi
worsen hepatotox identif predict biomark util
non-invas diagnost detail price commerci strategi
anticip volatil data present process
share trade initi view overal posit data
trend revers throughout day would exagger
next trade session close low pre-data
close price share recov march trend
upward april anticip thursday data expect
highli volatil throughout day net posit result
plenti competitor data consid year meet like
rememb regener data world nash also
curiou phase ii trial data emricasan msdc-
also look forward mri-pdff data gilead acc/fxr
combo madrig vike pbc highlight
clinic data oca/bezafibr combo elafibranor phase ii result
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc american biopharmaceut
compani focus develop novel synthet bile acid
analog treat chronic liver diseas pbc nafld nash
cirrhosi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
scenario intercept repres
credit compani on-going phase trial nash
increas growth rate ocaliva pbc nash largest
growth driver compani
grey scenario intercept repres
credit compani on-going phase trial nash use
po would surpris trial outright
failur believ scenario reflect worst-cas
valuat compani
addit intercept present easl
bezafibr improv effect obetichol acid cholestasi patient
effect obetichol acid liver function patient fibrosi due nash
inadequ respons udca among pbc patient routin care us
rise serum bilirubin even normal rang risk factor subsequ clinic
follow-up differ base treatment respons abstract
long-term assess effect obetichol acid patient primari biliari
cholang immun inflammatori marker abstract
long-term obetichol acid treatment associ improv collagen
morphometri patient primari biliari cholang abstract
chang lipid characterist respons obetichol acid target-pbc
respons obetichol acid target-pbc divers larg unit state real-
evalu anti-fibrot properti oca vitro system
morphometr collagen analysi discern anti-fibrot effect oca
obetichol acid reduc matrix metalloproteinas activ via ino modul
present interest us
pm pm efficaci patient primari biliari cholang
inadequ respons ursodeoxychol acid interim efficaci result
significantli reduc liver fat high dose patient
effect analogu pruritu patient
primari scleros cholang analysi phase multicent random
safeti toler efficaci volixibat apic sodium-depend
bile acid transport inhibitor adult non-alcohol steatohepat
interim analysi result phase studi
chang serum bile acid correl
one fibrogenesi biomark therapi patient
pm pm novel activ singl
dose significantli reduc steatosi liver fat mri-pdff inflamm alt
ast fibrogen activ nafld subject
pm pm partial inhibit de novo lipogenesi acetyl-coa
carboxylas inhibitor increas circul triglycerid
human suffici lower steatosi rat
pm pm ketohexokinas inhibitor administ
week reduc whole liver fat measur magnet reson imaging-proton
densiti fat fraction subject nonalcohol fatti liver diseas
pm pm month interim result larg phase
nash studi demonstr signific improv liver enzym glycem
pm pm multicent double-blind placebo-control random trial
emricasan subject nash cirrhosi sever portal hypertens
delta agonist demonstr favour efficaci safeti patient
primari biliari cholang inadequ respons ursodeoxychol acid
mri-pdff respons placebo treat patient predict
reduct balloon inflamm compon na nash resolut
serial liver biopsi studi
biomark clinic characterist associ non-alcohol
steatohepat fibrosi progress centaur studi
combin inhibitor nonsteroid fxr
agonist improv hepat steatosi biochemistri stiff patient
non-alcohol steatohepat
tropifexor farnesoid receptor agonist treatment non-
alcohol steatohepat interim result base baselin bodi mass index
first two part phase studi flight-fxr
pharmacokinet safeti pegbelfermin administ
abdomen upper arm normal overweight obes healthi
compani mention price
